Pfiz­er to cut 200 jobs at Michi­gan plant that makes Covid prod­ucts

Last year
People
R&D

As weight loss lead­ers boom, one biotech con­tender aban­dons its quest with Chap­ter 7 liq­ui­da­tion

Last year
Pharma

Out­look to con­duct an­oth­er tri­al for wet AMD drug; Cara strikes new roy­al­ty deal

Last year
News Briefing

In ear­ly look at ASH ab­stracts, BeiGene touts Brukin­sa da­ta, Cel­lec­tis com­pares in-house CAR-T to CD­MO CAR-T

Last year
R&D

Boehringer In­gel­heim plans PhI­II chron­ic kid­ney dis­ease tri­al for al­dos­terone-tar­get­ing drug af­ter mid-stage suc­cess

Last year
R&D

No­var­tis’ Plu­vic­to sup­ply ‘ful­ly un­con­strained,’ eyes man­u­fac­tur­ing ex­pan­sion

Last year
Manufacturing

Kro­nos Bio ax­es near­ly one-fifth of staff to pre­serve cash for two can­cer pro­grams

Last year
People
R&D

With IPO mon­ey, Neumo­ra eyes deals as CEO brings M&A chops from roles at Ab­b­Vie, JP Mor­gan

Last year
Deals

CNS biotech Rap­port snags a CFO vet­er­an from Karuna; Bris­tol My­ers’ new CEO to chair the board next year

Last year
Peer Review

Lex­eo Ther­a­peu­tics joins small class of 2023 biotech IPOs in $100M Nas­daq list­ing

Last year
Financing
Startups

Phath­om notch­es FDA ap­proval for Vo­quez­na to treat ero­sive GERD

Last year
Pharma
FDA+

Sen­ate Fi­nance Com­mit­tee seeks to ad­vance bi­par­ti­san PBM re­forms along­side oth­er health bills

Last year
FDA+
Law

Ot­su­ka part­ners with for­mer Olympic swim­mer on kid­ney dis­ease cam­paign

Last year
Pharma
Marketing

US ar­gues that As­traZeneca's IRA suit 'fares no bet­ter than the oth­er­s'

Last year
Pharma
Law

House Re­pub­li­cans threat­en FDA with sub­poe­na over al­leged in­ad­e­quate lab safe­ty over­sight

Last year
Pharma
FDA+

FDA par­tial­ly halts Nurix Ther­a­peu­tics’ can­cer tri­al as it im­proves man­u­fac­tur­ing process

Last year
Pharma
FDA+

Dai­ichi Sankyo to boost ADC man­u­fac­tur­ing; Eli Lil­ly looks to out­er space; new FDA ini­tia­tive for man­u­fac­tur­ing tech

Last year
Manufacturing

Ra­dio­phar­ma CD­MOs nav­i­gate sup­ply chain, raw ma­te­r­i­al chal­lenges as de­mand goes nu­clear

Last year
In Focus
Manufacturing

Mod­er­na cuts back on man­u­fac­tur­ing; Lil­ly eyes Moun­jaro sup­ply boost; GSK’s shin­gles vac­cine ‘un­con­strained’

Last year
Manufacturing

In­tel­lia sug­gests AT­TR amy­loi­do­sis gene edit­ing treat­ment has over a year of dura­bil­i­ty as it gears up for PhI­II

Last year
R&D
Cell/Gene Tx

Or­biMed and Third Rock’s Ter­re­mo­to Bio­sciences rais­es $175M for small mol­e­cule R&D

Last year
Financing
Startups

Pro­tag­o­nist's $50M mile­stone; Swiss biotech rais­es $27M; Kymera halts a PhI

Last year
News Briefing

Re­gen­eron ex­pects key Dupix­ent COPD da­ta this year amid Eylea's sales de­cline in the US

Last year
Pharma

Seres Ther­a­peu­tics sheds about 160 jobs to fo­cus on com­mer­cial C. diff pill

Last year
People
R&D
First page Previous page 251252253254255256257 Next page Last page
A service from the Financial Times